Tennessee Memory Disorders Foundation at CTAD 2026

Nov 16–19, 2026 Boston, MA ~1.7k attendees Website

Tennessee Memory Disorders Foundation takes part in 3 sessions at CTAD 2026 in Boston. Its program centres on real-world infusion of anti-amyloid antibodies in a community memory clinic. Its work reviews patient outcomes with donanemab and lecanemab and how blood biomarkers perform across patient groups.

OrganizationCTAD 2026 Attendance
tmdf.org
Clinical trial sites
Knoxville nonprofit memory clinic that diagnoses and treats dementia, gives infusion therapies and runs regional Alzheimer's trials.
Poster
Wed Nov 18
7:15am–5:30pm
Poster
Thu Nov 19
7:15am–5:00pm
Patient Outcomes and Real-World Treatment Review and Assessment of Infusion Therapies with Donanemab (P490)
Anti-amyloid and anti-tau therapies · Real-world data and access
Poster
Thu Nov 19
7:15am–5:00pm
Patient Outcomes and Real-World Treatment Review and Assessment of Infusion Therapies with Lecanemab (P491)
Anti-amyloid and anti-tau therapies · Real-world data and access

Explore the full CTAD 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Boston. Leave your work email and we’ll be in touch.

Privacy

Download the full CTAD 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Tennessee Memory Disorders Foundation

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction